Received May 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | UNK | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | OT |
HCP called regarding GARDASIL and/or GARDASIL 9. It's reported that the patient was "in her 20's at the time of the first vaccination" and missed her 2nd and 3rd dose in the GARDASIL series (HCP unclear whether it was GARDASIL or GARDASIL 9) and on; No other AE/No PQC.; This spontaneous report was received from a/an Pharmacist and refers to a(n) Adult female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date between 2014 and 2016 also reported when the patient was in her 20's, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), administered by Unknown route (lot # and expiration date were not reported) however, the reporter was unclear whether it was GARDASIL or GARDASIL 9. On an unknown date, the patient started therapy with Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL) or Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), administered by Unknown route (lot # and expiration date were not reported). The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), for the treatment of Prophylaxis. The HCP stated that they would be administering the remaining Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) series "starting where they left off", they had not yet received the 2nd and 3rd dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9). No adverse event reported. Lot # is being requested and will be submitted if received.